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I. Additional Computational Details 
 
1. Pre-processing of crystal structure templates for structure prediction 
For each validation case, hβ2AR and hM2, we determined the range of TM regions by taking a 
consensus of the helix assignment in the Protein Data Bank (PDB) of its active state structure and 
inactive structure, taken from the Orientations of Proteins in Membranes (OPM) database.(1) We then 
cropped out the TM regions and added missing atoms using tleap in AmberTools1.4.(2) To have 
meaningful comparisons of the energetics of structures sampled from inactive state crystal structure and 
from active state crystal structure, we minimized all these structures (TM regions only) using MPSim(3) 
with a convergence criterion of root mean square force (RMS force) = 0.25 kcal mol-1 Å-1 before 
proceeding to the conformational sampling steps.  
 
2. Constructing the hybrid templates 
For Validation Method 2.1 
We aligned the active state crystal structure to the inactive-state crystal structure using Visual Molecular 
Dynamics (VMD).(4) We considered only the backbone atoms in TM1-5 and TM7 in the alignment. 
Then we replaced the TM6 in the inactive-state crystal structure with the TM6 in the active-state crystal 
structure.  
	   2	  
 
For Validation Method 3.3 
We obtained an active state candidate, denoted S1, from coarse SuperBiHelix sampling of the inactive-
state crystal structure. Then we aligned the active-state crystal structure to S1 using VMD. We 
considered only the backbone atoms in the alignment. At last, we replaced the TM6 in S1 with the TM6 
in the active-state crystal structure.  
 
For application to hSSTR5 
We obtained a homology model of the target protein using an inactive-state crystal structure as the 
template, and did coarse SuperBiHelix to obtain an active-state candidate T1. We also obtained the 
homology model of the target protein using an active-state crystal structure as the template, and name 
this model as T2. Then we aligned T2 to T1 using VMD. We considered only the backbone atoms in the 
alignment. At last, we replaced the TM6 in T1 with the TM6 in T2. The x,y coordinates of the 
hydrophobic center (HPC) of the hybrid template remain to be that of T1.  
 
3. Energy scoring function in structure prediction 
Whenever energy ranking was performed in structure prediction procedures, we used energy ECNti which 
is the average energy of four types of energy: a) the total energy of the charged protein (CTotal), b) the 
interhelical energy of the charged protein (CInterH), which neglects the intrahelical energy of each 
chain, c) the total energy (NTotal), and d) the interhelical energy (NInterH) of the neutralized protein. 
 
4. Ligand docking 
Scanning regions in protein for docking 
The first step of GenDock(5, 6) is DarwinDock, which modifies the protein structure to replace the six 
types of hydrophobic residues by alanine, and then samples the complete set of poses for regions that 
could potentially bind a ligand. To do this sampling, the potential binding region is filled by SphGen 
with "spheres" having 2 Å overlaps with each other and the spheres classified into "boxes" of 10 Å 
sides. Boxes containing 75 or more spheres were kept. For docking purpose, we have discarded all 
spheres except for those that are in the extracellular half of the GPCR TMDs and are not potentially in 
contact with the membrane lipids (i.e. are in the interior of the GPCR helix bundle). 
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GenDock 
For each ligand conformation and for the “spheres” selected in the previous step, we generated 200 000 
poses without energy evaluation aiming at providing a complete set of poses. The poses were clustered 
into ~8000-9000 Voronoi families based on RMSD and the binding energy of the family head evaluated. 
Then for the top 10% of families, we evaluated the energy for all children. Then we selected the top 50 
based on each three energy scores: polar energy, hydrophobic energy, and total energy. Then for these 
150, we dealanized (mutating alanine back to the original hydrophobic residues) and optimized the side 
chains using SCREAM. Then the protein-ligand complexes (poses) were subject to minimization for 50 
steps. 
 
Docking procedure of agonists to hSSTR5 
For each ligand, we first did a conformational search using MacroModel 9.7(7) in Maestro 9.1.(8) For L-
817,818, we sampled 6 rotatable bonds . For F21, the –CH2-CH2-Ph group was first replaced by a 
methyl group. This modified molecule is labeled F21m. For F21m, 7 rotatable bonds were sampled. The 
conformational search was a torsional sampling of the rotatable bonds that could cause large 
conformational changes using a Monte Carlo Multiple Minimum (MCMM) method(9, 10) with the force 
field OPLS 2005.(11) The energy window for the generated structure to be kept was set to be 10.04 kcal 
mol-1. Then we clustered the resulting conformations with an RMSD cutoff of 2 Å. For L-817,818 and 
F21m, the clustering resulted in 18 and 8 distinct conformations respectively. Then each F21m 
conformation was modified into F21 by adding back the –CH2-Ph group with each of the 9 possible 
conformations. The ligand conformations were then docked to each candidate protein structure using our 
standard docking strategy, GenDock,(5, 6) described above. The charge distribution used in docking was 
obtained by the Mulliken population analysis using B3LYP/6-311G** in Jaguar 7.6.(12)  For each ligand 
and each docked protein, we collected 1000 lowest unified-cavity (UCav) energy complexes. Then for 
each ligand, we collected 15 lowest UCav energy complexes and matched ligands at different positions 
in these complexes into each of the protein conformations in these complexes. We did a simulated 
annealing on the resulting complexes’ ligands and residues within 10 Å from the ligands. In the end, we 
minimized each of the complexes. The final complexes were scored by snap binding energy (SnapBE). 
For each ligand, the lowest energy complex among all complexes with an active-state GPCR was 
selected as the final active-state pose, and the lowest energy complex among all complexes with an 
inactive-state GPCR was selected as the final inactive-state pose. 
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5. Molecular dynamics (MD) simulation 
Preparing the crystal structures of hβ2AR and the Gs protein for MD simulation 
Starting from the active-state crystal structure coupled with the Gs protein (PDB ID: 3SN6), we modeled 
the missing loops in the Gα domain of the G protein using the SWISS-MODEL server,(13) and built the 
missing loops in the GPCR with a Monte Carlo technique that grows geometrically allowed loop 
structures from the two TM ends. We then relaxed the modeled loops by simulated annealing of 10 
cycles (lowest temperature: 50 K, highest temperature: 600 K) followed by minimization till RMS force 
reached 0.25 kcal mol-1 Å-1. For the inactive-state case, we aligned the inactive-state crystal structure to 
the active-state crystal structure to match the agonist into the inactive-state structure. We then 
minimized the complex till RMS force reached 0.25 kcal mol-1 Å-1 and did simulated annealing of the 
binding site within 6 Å of the ligand, followed by minimization.  
 
Loop building of hSSTR5 
We modeled ICL1, ECL1 and ECL2 from mOPRM crystal structure (PDB ID: 4DKL)(14) using 
homology modeling. The remaining loops, ICL2, ICL3 and ECL3, were built with a Monte Carlo 
technique that grows geometrically allowed loop structures from the two fixed TM ends. Then we added 
the C-terminus of hSSTR5 up to the C-terminus of Helix8 (C320) by attaching Helix8 of the template 
after aligning their NPxxY motifs followed by mutating to hSSTR5. In addition, we added the N-
terminus from residue 36 to 38. Minimization was then carried out on the final structure while keeping 
the TM domains (except the end residues) fixed until energy was converged. 
 
Modeling Gαi  
We used SWISS-MODEL(13) to model Gαi (UniProt ID: P63096, canonical) from Gαs in the G protein 
heterotrimer crystalized with hβ2AR (PDB ID: 3SN6).(15) Using MPSim,(3) we minimized Gαi in 
vacuum until the RMS force is lowered to 0.1 kcal mol-1 Å-1. Then Gαi was placed with ActiveConf2 by 
aligning ActiveConf2 to hβ2AR in 3SN6 and aligning Gαi to Gαs in 3SN6. Only backbone atoms were 
considered in the alignment. 
 
For the ActiveConf2+Gαi complex, we used MPSim to optimize all loops plus one more residue at each 
end of each TM the GPCR together with residues 352 to 354 of Gαi in the ActiveConf2+Gαi complex. 
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Building the lipid/water environment for hβ2AR 
1) For the agonist+GPCR complex: We used Visual Molecular Dynamics (VMD),(4) to insert the  
prepared complex into a 75 Å × 85 Å lipid bilayer structure (for the inactive state) or into a 75 Å × 95 Å 
lipid bilayer structure (for the active state). This system was then placed into a water box with a total of 
~11300 (for the inactive state) water molecules or ~13000 (for the active state) water molecules in the 
15 Å and 35 Å thick space on the extracellular and intracellular sides of the lipid bilayer.  
2) For the agonist+GPCR+Gαs complex: Using VMD, the prepared agonist+GPCR+Gαs complex was 
inserted into a 120 Å × 130 Å lipid bilayer structure. This system was then placed into a water box with 
a total of ~39500 water molecules in the 15 Å and 60 Å thick space on the extracellular and intracellular 
sides of the lipid bilayer. 
3) For Gαs alone: Using VMD, the prepared Gαs protein was placed into a rectangular water box with 10 
Å thick of water padded on each of x-, y-, z- direction of the protein. There were a total of ~19400 water 
molecules. 
4) For the agonist alone: Using VMD, the agonist taken from the prepared agonist+GPCR+Gαs complex 
was placed into a rectangular water box with 15 Å thick of water padded on each of x-, y-, z- direction 
of the molecule. There were a total of ~1700 water molecules. 
 
For all the three cases above, in the end, Na+ and Cl- ions were placed into the system using tleap for a 
physiological NaCl concentration (0.9% w/v) and a neutral system. 
 
Building the lipid/water environment for hSSTR5 
1) For ligand-bound GPCR: Using VMD, the final hSSTR5 structure with loops built was inserted into a 
75 Å × 75 Å lipid bilayer structure. The system was then placed into a water box with a total of ~8300 
water molecules in the 15 Å and 25 Å thick space on the extracellular and intracellular sides of the lipid 
bilayer.  
2) For agonist+GPCR+Gαi complex: Using VMD, the agonist+GPCR+Gαi complex was inserted into a 
120 Å × 100 Å lipid bilayer structure. The system was then placed into a water box with a total of 
~29600 water molecules in the 15 Å and 60 Å thick space on the extracellular and intracellular sides of 
the lipid bilayer. 
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3) For Gαi alone: Using VMD, the modeled Gαi was placed into a rectangular water box with 10 Å thick 
of water padded on each of x-, y-, z- direction of the protein. There were a total of ~20800 water 
molecules. 
4) For the agonist alone: Using VMD, the agonist taken from the agonist+GPCR+Gαi complex was 
placed into a rectangular water box with 15 Å thick of water padded on each of x-, y-, z- direction of the 
molecule. There were a total of 1855 water molecules. 
 
For all the three cases above, in the end, Na+ and Cl- ions were placed into the system with tleap for a 
physiological NaCl concentration and a neutral system. 
 
MD simulation protocol 
MD_Step1) With the ligand and TM regions of the receptor fixed, the loops and Helix8 of the receptor, 
lipids and water molecules in the system were minimized for 10000 steps using the conjugate gradient 
method. In the case of the agonist+GPCR+Gα complex, Gα is fixed in this step too. In the case of Gα 
alone in solvent, only Gα is fixed in this step, and the minimization was carried out for 5000 steps. 
MD_Step2) With the ligand and TM regions of the receptor fixed, the loops and Helix8 of the receptor, 
the lipids and water molecules were equilibrated at 310 K and 1 atm for 1 ns using the NPT ensemble. 
This allowed the water molecules to defuse into the ligand-protein system filling any artificial voids in 
the simulation system. In the case of the agonist+GPCR+Gα complex, Gα is fixed in this step too. In the 
case of Gα alone in solvent, only Gα is fixed in this step, and the equilibration was for 1.5 ns. 
MD_Step3) The whole system was then minimized for 10000 steps using the conjugate gradient method. 
In the case of Gα alone in solvent, the minimization was carried out for 5000 steps. 
MD_Step4) The whole system was heated from 0 K to 310 K in hundreds of ps and then equilibrated 
using the NPT ensemble for a total of 51 ns MD simulation. 
 
For the simulation of apo-GPCR+Gα, we took the last frame of agonist+GPCR+Gα complex from the 
above procedure, removed the ligand from the system, adjusted the number of Na+ or Cl- ions to make 
the system neutral again if the ligand was charged, and repeated the above MD protocol MD_Step1) to 
MD_Step4) with the all parts of the proteins fixed in MD_Step1).  
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II. Supporting Tables and Figures 
 
 
TABLE S1 Comparison of R36 between inactive-state and active-state GPCR crystal structures. R36 is 
the minimal approach distance between the backbone atoms of the intracellular ends of TM3 and TM6, 
defined in the Materials and Methods section. R36 of active state structure is R36(a); R36 of inactive state 
structure is R36(i).  
Protein (PDB ID) Protein Description Coupled Protein R36 (Å) R36(a) – R36(i) (Å) 
hβ2AR (3SN6)(15) active 
G protein heterotrimer 
13.83 4.12 
hβ2AR 
(2RH1)(16) inactive 
- 
9.71 - 
bRho (3PQR)(17) active (metarhodopsin II) 
Gα C-terminal fragment 
11.44 3.69 
bRho (1U19)(18) inactive (rhodopsin) 
- 
7.75 - 
hM2 (4MQS)(19) active 
G protein mimetic 
camelid antibody 
fragment 11.34 2.84 
hM2 (3UON)(20) inactive 
- 
8.50 - 
mOPRM 
(5C1M)(21) active 
G protein mimetic 
camelid antibody 
fragment 12.21 5.08 
mOPRM 
(4DKL)(14) inactive 
- 
7.13  
hAA2AR (2YDO) 
(22) agonist-bound 
- 
7.48 1.34 
hAA2AR 
(3EML)(23) antagonist-bound 
- 
6.14 - 
 
 
TABLE S2 Summary of structural features and energies of hβ2AR and hM2 optimal structures generated 
from different methods. The “Structure Identifier” corresponds to the numbers in Fig. 1. Each RMSD 
value is between the backbone atoms of the resulting optimal structure of the particular method and the 
backbone atoms of the active-state crystal structure preprocessed according to Supporting Materials and 
Methods. For hM2, the second best choice of 3.2 is also listed for comparison. Unlike hβ2AR for which 
the inactive state is 73.8 kcal mol-1 more stable than the active state, this value for hM2 is only 3.7 kcal 
mol-1. Therefore, the number of 7-helix bundles built from SuperBiHelix results is increased to 2500 to 
capture more candidates in the active-like regime. (For hβ2AR, building 1000 or 2500 bundles has the 
same the final results shown in this table.) While hM2’s lowest-energy structure from AfromI_Fine that 
satisfies the active-like R36 criterion (upper row of 3.2 in the table) has a much larger RMSD than 
Structure 3.1 to the active-state crystal structure, the second-lowest-energy structure (lower row of 3.2 in 
the table) has an improved RMSD comparing to 3.1. This suggests selecting a small number of diverse 
structures from the potential energy well may help in active-state structure prediction as well. 
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Structure / 
Method 
Identifier 
Method Name 
Method Description hβ2AR hM2 
Sampling 
Target Starting Structure Sampling Method 
ECNti 
(kcal 
mol-1) 
RMSD to Target 
Crystal Structure 
(Å) 
R36 
(Å) 
ECNti 
(kcal 
mol-1) 
RMSD to Target 
Crystal Structure 
(Å) 
R36 
(Å) 
Active crystal 
structure - 
Active 
State 
Active crystal 
structure None - 0.00 13.72 - 0.00 11.14 
Inactive 
crystal 
structure 
- Active State 
Active crystal 
structure None - 2.48 9.71 - 2.30 8.55 
1.1 AfromA_Coarse Active state 
Active crystal 
structure Coarse -146.8 0.04 13.68 -168.5 0.37 11.15 
1.2 AfromA_Fine Active state 
Active crystal 
structure Fine after Coarse -146.8 0.04 13.68 -168.5 0.37 11.15 
2.1 AfromH_Coarse Active state 
Active crystal 
TM6 + inactive 
other TMs 
Coarse -158.0 1.41 15.12 -96.9 1.55 13.60 
2.2 AfromH_Fine Active state 
Active crystal 
TM6 + inactive 
other TMs 
Fine after Coarse -196.9 1.48 14.64 -100.3 1.69 13.45 
3.1 AfromI_Coarse Active state 
Inactive crystal 
structure Coarse -95.0 1.79 12.85 -77.4 1.94 14.45 
3.2 AfromI_Fine Active state 
Inactive crystal 
structure Fine after Coarse -114.5 1.86 13.41 
-127.2 2.68 15.20 
-111.6 1.92 15.22 
3.3 AfromIH_Fine Active state 
Inactive crystal 
structure 
Fine after replacing TM6 
of 3.1 result by active 
crystal structure TM6 
-169.5 1.47 14.03 -113.2 1.52 14.44 
Inactive 
crystal 
structure 
- Inactive state 
Inactive crystal 
structure None - 0.00 9.71 - 0.00 8.55 
4.1 IfromI_Coarse Inactive state 
Inactive crystal 
structure Coarse -220.6 0.07 9.72 -168.8 0.04 8.54 
4.2 IfromI_Fine Inactive state 
Inactive crystal 
structure Fine after Coarse -220.6 0.07 9.72 -168.8 0.04 8.54 
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TABLE S3 Summary of structural features and energies of a) hβ2AR and b) hM2 optimal structures 
generated from different methods. The “Method Identifier” corresponds to the numbers in Fig. 1. Each 
RMSD value is between the backbone atoms of the resulting optimal structure of the particular method 
and the backbone atoms of the active-state crystal structure. For TM4, none-zero Δφ values do not have 
as big effect as Δφ on the orientations of other TMs because the absolute value of θ for TM4 is close to 
zero.  a)	  
Structure / 
Method 
Identifier Method Name Δθ (°) Δφ (°) Δη (°) 
ECNti  
(kcal mol-1) 
RMSD to 
crystal active 
(Å) 
R36 
(Å) 
 
 
H1 – 
H7 H1 H2 H3 H4 H5 H6 H7 H1 H2 H3 H4 H5 H6 H7 
   Active 
crystal 
structure - - - - - - - - - - - - - - - - N/A 0.00 13.72 
Inactive 
crystal 
structure - - - - - - - - - - - - - - - - N/A 2.48 9.71 
1.1 AfromA_Coarse 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 -146.8 0.04 13.68 
1.2 AfromA_Fine 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 -146.8 0.04 13.68 
2.1 AfromH_Coarse 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 -158.0 1.44 15.12 
2.2 AfromH_Fine 0 0 0 0 -15 0 15 15 0 0 0 0 0 0 0 -196.9 1.48 14.64 
3.1 AfromI_Coarse 0 0 0 0 0 0 -45 0 0 0 0 0 0 -30 0 -95.0 1.79 12.85 
3.2 AfromI_Fine 0 0 0 0 -15 0 -75 30 0 0 0 0 0 -60 0 -114.5 1.86 13.41 
3.3 AfromIH_Fine 0 0 0 0 15 0 15 15 0 0 0 0 0 0 0 -169.5 1.47 14.03 
4.1 IfromI_Coarse 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 -220.6 2.47 9.72 
4.2 IfromI_Fine 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 -220.6 2.47 9.72 
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b) 
Structure / 
Method 
Identifier Method Name Δθ (°) Δφ (°) Δη (°) 
ECNti  
(kcal 
mol-1) 
RMSD to 
crystal 
active 
(Å) 
R36 
(Å) 
 
 H1 H2 H3 H4 H5 H6 H7 H1 H2 H3 H4 H5 H6 H7 H1 H2 H3 H4 H5 H6 H7 
   Active 
crystal 
structure - - - - - - - - - - - - - - - - - - - - - - N/A 0.00 11.14 
Inactive 
crystal 
structure - - - - - - - - - - - - - - - - - - - - - - N/A 2.30 8.55 
 
1.1 AfromA_Coarse 0 0 0 0 0 0 0 0 0 0 -45 0 0 0 0 0 0 0 0 0 0 -168.5 0.37 11.15 
1.2 AfromA_Fine 0 0 0 0 0 0 0 0 0 0 -45 0 0 0 0 0 0 0 0 0 0 -168.5 0.37 11.15 
2.1 AfromH_Coarse 0 0 0 0 0 0 -15 0 0 0 0 0 0 -90 0 0 0 0 0 -30 0 -96.9 1.55 13.60 
2.2 AfromH_Fine 0 0 0 0 0 0 0 0 0 0 -15 15 15 -60 0 0 0 0 0 -30 0 -100.3 1.69 13.45 
3.1 AfromI_Coarse 0 0 0 0 15 15 -15 0 0 0 0 0 -90 0 0 0 0 0 0 0 0 -77.4 1.94 14.45 
3.2 AfromI_Fine 
0 0 0 0 30 15 0 0 0 0 -15 15 -60 0 0 0 0 0 -30 0 0 -127.2 2.68 15.20 
0 0 0 0 15 15 0 0 0 0 -15 30 -60 15 0 0 0 0 0 0 0 -111.6 1.92 15.22 
3.3 AfromIH_Fine 0 0 0 0 0 0 0 0 0 0 0 15 0 15 0 0 0 0 0 -30 0 -113.2 1.52 14.44 
4.1 IfromI_Coarse 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 -168.8 0.04 8.54 
4.2 IfromI_Fine 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 -168.8 0.04 8.54 
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TABLE S4 Summary of starting structures (Methods 3.1, 4.1) and best resulting structures (Method 3.2, 
3.3, 4.2.x) of sampling hSSTR5 conformations using different strategies. Method 3.x are active state 
samplings, and Method 4.x are inactive state samplings. The original homology template is from the 
mOPRM inactive-state crystal structure. The methods used are outlined in Fig. S1 and detailed in our 
previous publication.(25) 
Structure  / 
Method 
Identifier Method Name Δθ (°) Δφ (°) Δη (°) 
ECNti  
(kcal mol-1) R36 (Å) 
  
H1 – 
H5, H7 H6 H1 H2 H3 H4 H5 H6 H7 H1 H2 H3 H4 H5 H6 H7 
  Homology w/ 
mOPRM 
inactive-state 
crystal 
structure - 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 N/A 6.04 
3.1 AfromI_Coarse 0 0 0 0 0 0 0 -90 0 0 0 0 0 30 270 0 -265.8 11.34 
3.2 
(ActiveConf1) AfromI_Fine  0 0 0 0 0 0 0 -60 -15 0 0 0 0 30 270 0 -313.2 10.71 
3.3 
(ActiveConf2) AfromIH_Fine  0 -15 0 0 -15 0 -30 -60 0 0 0 0 0 30 240 0 -306.6 10.20 
4.1 IfromI_Coarse 0 0 0 0 0 90 0 0 0 0 0 0 -30 30 0 0 -303.3 6.01 
4.2.1 
(InactiveConf1) IfromI_Fine  0 0 0 0 0 105 0 -15 0 0 0 0 -30 0 0 0 -350.7 7.18 
4.2.2 
(InactiveConf2) IfromI_Fine 0 0 0 0 -15 60 30 15 0 0 0 0 0 60 0 0 -345.7 7.59 
4.2.3 
(InactiveConf3) IfromI_Fine 0 0 0 0 -15 60 -30 15 0 0 0 0 0 30 0 0 -328.9 7.56 
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TABLE S5 Best pose of L-817,818 and F21 docked to active structures determined by lowest snap 
binding energy (SnapBE). 
Pose Name Ligand Protein Structure SnapBE (kcal mol-1) 
L_i2 L-817,818 InactiveConf2 -118.32 
L_a2 L-817,818 ActiveConf2 -106.05 
F_i2 F21 InactiveConf2 -99.41 
F_a2 F21 ActiveConf2 -92.39 
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InactiveConfs! ActiveConfs!
(Type 1)!
ActiveConfs!
(Type 2)!
Initial values of 
(x,y,h,θ,φ,η) and 
helix shape $
(Templates)$
Coarse sampling of 
(θ,φ,η) for a rough 
potential energy 
surface$
Identifying different 
energy wells by 
TM3-6 distance (R36)$
Fine sampling of 
(θ,φ,η) to obtain 
local minimum of 
each well$
Selected final 
structures$
Inactive crystal structure template!
BiHelix/CombiHelix and 
Coarse SuperBiHelix/
SuperComBiHelix!
Inactive structure: the 
lowest energy structure 
with TM3-6 ionic lock!
Potentially active structure: lowest 
energy with R36 > R36(i) + R!
Replace TM6 with TM6 
mutated from active 
hβ2AR template!
TM6 shape from 
active-state 
template structure$
Fine SuperBiHelix/SuperComBiHelix!
Complete sampling of 
η: BiHelix/CombiHelix 
(optional)!
 
 
FIGURE S1 Schematic view of ActiveGEnSeMBLE. R36 is the minimal approach distance between the 
backbone atoms of the intracellular ends of TM3 and TM6, defined in the Materials and Methods 
section. R36(i) is that of the inactive structure. R is a distance, usually chosen around 4 Å. Among all 
cases involved in this paper, the optional step was only carried out for hSSTR5 structure prediction, and 
it was found to be unnecessary as the final selected structures are the same as those without this step 
carried out. The sampling space of BiHelix is Δη from 0 to 360° in 30° increments. If not noted 
otherwise, the sampling space of Coarse SuperBiHelix is Δθ: 0, ±15°; Δφ: 0, ±45°, ±90°; Δη: 0, ±30°, 
selected angles from BiHelix/CombiHelix, starting with the best from BiHelix/CombiHelix. The 
sampling space of Fine SuperBiHelix is Δθ: 0, ±15°; Δφ: 0, ±15°, ±30°; Δη: 0, ±30°. The active state 
template for TM6 is chosen to be hβ2AR (PDB ID: 3SN6) in this study because it is by far the only 
GPCR co-crystalized with a full G protein heterotrimer.  
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h!2AR  
bRho  
G"s  arrestin 
predicted 
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G"t  
 
FIGURE S2 Predicted minimum-energy hβ2AR structure (cyan) in one of the energy wells can 
accommodate arrestin (green) but not Gαs (yellow). An energy well is defined by clustering the 
structures with R36 values within 0.25 Å of each other. We positioned the Gαs protein and the arrestin by 
aligning hβ2AR (orange) in its Gαs-coupled crystal structure (PDB ID: 3SN6)(15), bRho (grey) in its 
arrestin-coupled crystal structure (PDB ID: 4ZWJ)(24) and bRho (pink) in its Gαt-C-terminus-coupled 
crystal structure (PDB ID: 3PQR)(17) to the predicted hβ2AR structure without changing the relative 
orientation within each crystal structure. We find the minimum energy structure of hβ2AR in the R36 ≈ 
12.4 Å well clashes with Gαs but not with arrestin. It is hard to determine by speculation whether it 
distinguishes arrestin with the Gi protein because the C-terminus helix of Gαt subunit (red) co-
crystalized with the active-state bRho is similar in position with the part of arrestin inside the GPCR. 
(Therefore, similar analysis was not carried out on hM2 which couples with the Gi protein instead of Gs 
in vivo.) This structure is from the ensemble of structures generated using Method 3.2 which uses the 
inactive-state TM shapes for all TMs. It is characterized by Δθ = 0 for all helices; Δφ = -15°, 0, 0, 15°, 0, 
-30°, 15°; Δη = 0, 0, 0, 0, 0, -30°, 0 with the values ordered from TM1 to TM7. It has ECNti = -114.1 kcal 
mol-1. The coordinates of this predicted structure are included in the Supporting Material as a separate 
file in the PDB format.  
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FIGURE S3 Potential energy profile from sampling hM2 conformations. The black curve is an 
illustration showing how our sampling results can qualitatively be translated into a potential energy 
curve using R36 as the x-axis and does not quantitatively represent any real data. Results of the coarse 
sampling starting from the inactive-state crystal structure are in blue circles. Starting from Structure 3.1, 
results of methods that generated Structures 3.2 and 3.3 are shown in red crosses and red squares 
respectively. Starting from the Structure 4.1, results of the fine sampling that generated Structure 4.2 are 
in green dots. Every blue arrow points from a starting structure towards the optimal structure from the 
corresponding sampling method.  
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FIGURE S4 Energy profile from hSSTR5 samplings. The black curve is an illustration showing how our 
sampling results can qualitatively be translated into a potential energy curve using R36 as the x-axis and 
does not quantitatively represent any real data. Results of the coarse sampling are in blue circles. 
Starting from Structure 3.1, results of methods that generated Structures 3.2 (ActiveConf1) and 3.3 
(ActiveConf2) are shown in red crosses and red squares respectively. Starting from the Structure 4.1, 
results of the fine sampling that generated Structures 4.2.1, 4.2.2 and 4.2.3 (InactiveConf1,2,3) are in 
green dots. Every blue arrow points from a starting structure towards the optimal structure from the 
corresponding sampling method. 
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FIGURE S5 Antagonists series docked to hSSTR5 predicted structures. 	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FIGURE S6 Structures of the docked agonists a) L-817,818 (Ki = 0.4 nM) and b) F21 (IC50 = 0.56 nM).  
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FIGURE S7 a) 3D visualization of the docking pose F_i2, the lowest energy complex with agonist F21.  
b) 3D visualization of the docking pose F_a2. The ligand is shown in purple. c) Ligand interaction 
diagram (LID) of the pose F_i2. d) LID of the pose F_a2. LIDs are generated by Maestro9.3.(26) The 
cutoff distance for the residues shown is 4.0 Å. Hydrophobic interaction: green; polar interaction: blue; 
hydrogen bonds (cutoff distance 2.5 Å): purple arrows; π-π stacking: straight green lines. 
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FIGURE S8 a) 3D visualization of the docking pose L_i2, the lowest energy complex with agonist L-
817,818.  b) 3D visualization of the docking pose L_a2. The ligand is shown in purple. c) Ligand 
interaction diagram (LID) of the pose L_i2. d) LID of the pose L_a2. LIDs are generated by 
Maestro9.3.(26) The cutoff distance for the residues shown is 4.0 Å. Hydrophobic interaction: green; 
polar interaction: blue; hydrogen bonds (cutoff distance 2.5 Å): purple arrows; π-π stacking: straight 
green lines. 
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FIGURE S9 Fluctuation of R36 of hSSTR5 during 51 ns molecular dynamics simulation starting from 
the predicted inactive-state structure. 
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FIGURE S10 Fluctuation of R36 of hSSTR5 during 51 ns molecular dynamics simulation starting from 
the predicted active-state structure without the presence of the Gα protein. 
 
	   23	  
0 5 10 15 20 25 30 35 40 45 50
9
9.5
10
10.5
11
11.5
12
12.5
13
13.5
14
Time / ns
R 3
6 /
 Å
Fluctuation of R36 During 51 ns of MD
 
 
w/ agonist
apo
 
FIGURE S11 Fluctuation of R36 of hSSTR5 during 51 ns molecular dynamics simulation starting from 
the predicted active-state structure in complex with the Gα protein. 
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FIGURE S12 Energy profile of hSSTR5 during activation. The horizontal bars are ER obtained 
according to the Materials and Methods section. The dashed horizontal bar is fictitious. “Inactive”, 
“intermediate” and “active” states in the figure are defined as R36 < 8 Å, 8 Å < R36 < 11 Å, and R36 > 11 
Å respectively. 
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FIGURE S13 Energy profile of the system during hSSTR5 activation. The horizontal bars are ETotal 
calculated according to the Materials and Methods section. The dashed horizontal bar is fictitious. 
“Inactive”, “intermediate” and “active” states in the figure are defined as R36 < 8 Å, 8 Å < R36 < 11 Å, 
and R36 > 11 Å respectively. 
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FIGURE S14 a) The salt bridge between L-817,818 (the agonist) and D862.50 of hSSTR5 is not present 
during the MD simulation of the agonist+InactiveConf2 complex. Instead, water molecules are 
surrounding D862.50. Water molecules within 10 Å of the side chain of D862.50 are displayed. b) A salt 
bridge between L-817,818 and D862.50 of hSSTR5 is formed during the MD simulation of the 
agonist+ActiveConf2+Gαi complex. In addition, there is π-π stacking between L-817,818 and W2616.48 
in the agonist+ActiveConf2+Gαi complex. There is no water molecule within 10 Å of the side chain of 
D862.50. c) The presence of the transmission switch: W2616.48 and F2576.44 are oriented towards P2135.50 
in ActiveConf2 (right panel) but not in InactiveConf2 (left panel) partly due to the rotation of TM6. The 
secondary structure in agonist+InactiveConf2 is shown in grey, and that in agonist+ActiveConf2+Gαi is 
shown in orange. Carbons in the residues on hSSTR5 are shown in cyan. The agonist carbon atoms are 
shown in purple.  
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FIGURE S15 Distance between the N atom in an amine group of L-817,818 and a carboxylic acid 
oxygen atom in D862.50 of hSSTR5 along the trajectory of MD simulation of the 
agonist+ActiveConf2+Gαi complex. 
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FIGURE S16 Distance between the N atom in an amine group of L-817,818 (the same amine group in 
Fig. S15) and a carboxylic acid oxygen atom in D862.50 of hSSTR5 along the trajectory of MD 
simulation of the agonist+InactiveConf2 complex. 
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FIGURE S17 Fluctuation of R36 of hβ2AR during 51 ns molecular dynamics simulation starting from the 
inactive-state structure. 
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FIGURE S18 Fluctuation of R36 of hβ2AR during 51 ns molecular dynamics simulation starting from the 
active-state structure. 
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FIGURE S19 Energy profile of hβ2AR during activation. The horizontal bars are ER obtained according 
to the Materials and Methods section. “Inactive”, “intermediate” and “active” states in the figure are 
defined as R36 < 10 Å, 10 Å < R36 < 13 Å, and R36 > 13 Å respectively. 
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FIGURE S20 Energy profile of the system during hβ2AR activation. The horizontal bars are ETotal 
calculated according to the Materials and Methods section. “Inactive”, “intermediate” and “active” states 
in the figure are defined as R36 < 10 Å, 10 Å < R36 < 13 Å, and R36 > 13 Å respectively. 
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FIGURE S21 Qualitative energy landscape of hβ2AR from experiments. This figure is adapted from 
Manglik et al. 2015. Cell 161:1101-1111.(27)  
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